Cannabidiol with clobazam for treating seizures associated with Dravet syndrome - guidance (TA614)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
18 December 2019

Abstract

Evidence-based recommendations on cannabidiol (Epidyolex) with clobazam for seizures associated with Dravet syndrome in people aged 2 years and older.

Is this guidance up to date?

Next review: 2022

Commercial arrangement

There is a simple discount patient access scheme for cannabidiol. Contact medinfo@gwpharm.com for details.

Guidance development process

How we develop NICE technology appraisal guidance